table of content
1 Introduction to Research & Analysis Reports
1.1 CAR-T Therapy in Haematological Malignancy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global CAR-T Therapy in Haematological Malignancy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global CAR-T Therapy in Haematological Malignancy Overall Market Size
2.1 Global CAR-T Therapy in Haematological Malignancy Market Size: 2022 VS 2032
2.2 Global CAR-T Therapy in Haematological Malignancy Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top CAR-T Therapy in Haematological Malignancy Players in Global Market
3.2 Top Global CAR-T Therapy in Haematological Malignancy Companies Ranked by Revenue
3.3 Global CAR-T Therapy in Haematological Malignancy Revenue by Companies
3.4 Top 3 and Top 5 CAR-T Therapy in Haematological Malignancy Companies in Global Market, by Revenue in 2022
3.5 Global Companies CAR-T Therapy in Haematological Malignancy Product Type
3.6 Tier 1, Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Players in Global Market
3.6.1 List of Global Tier 1 CAR-T Therapy in Haematological Malignancy Companies
3.6.2 List of Global Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global CAR-T Therapy in Haematological Malignancy Market Size Markets, 2022 & 2032
4.1.2 Allogeneic
4.1.3 Autologous
4.2 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
4.2.1 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue, 2018-2023
4.2.2 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue, 2024-2032
4.2.3 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global CAR-T Therapy in Haematological Malignancy Market Size, 2022 & 2032
5.1.2 Hospitals
5.1.3 Cancer Research Centers
5.1.4 Others
5.2 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
5.2.1 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue, 2018-2023
5.2.2 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue, 2024-2032
5.2.3 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global CAR-T Therapy in Haematological Malignancy Market Size, 2022 & 2032
6.2 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
6.2.1 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue, 2018-2023
6.2.2 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue, 2024-2032
6.2.3 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032
6.3.2 US CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.3.3 Canada CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.3.4 Mexico CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032
6.4.2 Germany CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.3 France CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.4 U.K. CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.5 Italy CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.6 Russia CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.7 Nordic Countries CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.8 Benelux CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032
6.5.2 China CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.5.3 Japan CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.5.4 South Korea CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.5.5 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.5.6 India CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032
6.6.2 Brazil CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.6.3 Argentina CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032
6.7.2 Turkey CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.7.3 Israel CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.7.4 Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.7.5 UAE CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
7 CAR-T Therapy in Haematological Malignancy Companies Profiles
7.1 Celgene (Juno Therapeutics)
7.1.1 Celgene (Juno Therapeutics) Company Summary
7.1.2 Celgene (Juno Therapeutics) Business Overview
7.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.1.4 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.1.5 Celgene (Juno Therapeutics) Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.2.4 Novartis CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Gilead (Kite Pharma)
7.3.1 Gilead (Kite Pharma) Company Summary
7.3.2 Gilead (Kite Pharma) Business Overview
7.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.3.4 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.3.5 Gilead (Kite Pharma) Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.4.4 Pfizer CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 CARsgen Therapeutics
7.5.1 CARsgen Therapeutics Company Summary
7.5.2 CARsgen Therapeutics Business Overview
7.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.5.4 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.5.5 CARsgen Therapeutics Key News & Latest Developments
7.6 Autolus Therapeutics
7.6.1 Autolus Therapeutics Company Summary
7.6.2 Autolus Therapeutics Business Overview
7.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.6.4 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.6.5 Autolus Therapeutics Key News & Latest Developments
7.7 Aurora BioPharma
7.7.1 Aurora BioPharma Company Summary
7.7.2 Aurora BioPharma Business Overview
7.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.7.4 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.7.5 Aurora BioPharma Key News & Latest Developments
7.8 Sorrento Therapeutics
7.8.1 Sorrento Therapeutics Company Summary
7.8.2 Sorrento Therapeutics Business Overview
7.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.8.4 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.8.5 Sorrento Therapeutics Key News & Latest Developments
7.9 Mustang Bio
7.9.1 Mustang Bio Company Summary
7.9.2 Mustang Bio Business Overview
7.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.9.4 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.9.5 Mustang Bio Key News & Latest Developments
7.10 Bluebird Bio
7.10.1 Bluebird Bio Company Summary
7.10.2 Bluebird Bio Business Overview
7.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.10.4 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.10.5 Bluebird Bio Key News & Latest Developments
7.11 Collectis
7.11.1 Collectis Company Summary
7.11.2 Collectis Business Overview
7.11.3 Collectis CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.11.4 Collectis CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.11.5 Collectis Key News & Latest Developments
7.12 Allogene Therapeutics
7.12.1 Allogene Therapeutics Company Summary
7.12.2 Allogene Therapeutics Business Overview
7.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.12.4 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.12.5 Allogene Therapeutics Key News & Latest Developments
7.13 Celyad
7.13.1 Celyad Company Summary
7.13.2 Celyad Business Overview
7.13.3 Celyad CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.13.4 Celyad CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.13.5 Celyad Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
